Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Jazz Pharmaceuticals buys biotechnology firm Cavion for £259m
As per terms of the deal, the former Cavion shareholders have secured an upfront payment of $52.5m (£43.5m). They are also eligible to receive additional payments of around
As per terms of the deal, the former Cavion shareholders have secured an upfront payment of $52.5m (£43.5m). They are also eligible to receive additional payments of around
Aquinox Pharmaceuticals, Inc. will be renamed Neoleukin Therapeutics, Inc. and will trade under the new ticker symbol “NLTX” beginning on Monday, August 12, 2019, on the Nasdaq Global
The company has announced positive OS results from the phase III randomised, double-blinded and multi-centre trial of Tagrisso in previously-untreated patients with locally-advanced or metastatic non-small cell lung
The updated preliminary Phase 3 clinical data will serve as the basis for the anticipated initiation of the Company’s BLA submission in 4Q 2019 “After two very positive
The FDA indicated that efficacy data from an additional clinical trial will be needed to support a resubmission. Kala continues to enroll patients in its ongoing STRIDE 3
The deal also includes an additional payment of $360m (£296.2m) based on achievement of pre-defined development milestones. The total investment in BlueRock is valued at around $1bn (£823m),
Vesselon will use Imagent to create novel therapeutic complexes in four classes of cancer drugs: cytokines, oncolytic viruses, monoclonal antibodies, and nucleic acid constructs. Vesselon incorporates Imagent into
Results from the trial showed a statistically-significant and clinically-meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) with Lynparza vs. enzalutamide or abiraterone in men with
As per terms of the merger deal, Cambrex shareholders will secure $60 (£49.3) in cash for each share of Cambrex common stock, representing a 47.1% premium to its
“To help support the long-term health of people living with HIV, it is ideal that treatment regimens deliver both durable viral suppression and a demonstrated tolerability profile,” said